Skip to Content


In the US, Rituximab (rituximab systemic) is a member of the following drug classes: antirheumatics, CD20 monoclonal antibodies and is used to treat Bullous Pemphigoid, Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Evan's Syndrome, Focal Segmental Glomerulosclerosis, Follicular Lymphoma, Granulomatosis with Polyangiitis, Idiopathic Thrombocytopenic Purpura, Mantle Cell Lymphoma, Microscopic polyangiitis, Non-Hodgkin's Lymphoma, Pemphigoid, Pemphigus, Pemphigus Vulgaris and Rheumatoid Arthritis.

US matches:



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Chemical Formula


Molecular Weight


Therapeutic Categories


Antineoplastic agent

Microtubule inhibitor

Biological response modifier, BRM

Anti-CD20 monoclonal antibody

Chemical Name

Immunoglobulin G 1 (human-mouse monoclonal IDEC-C2B8 gama 1-chain anti-human antigen CD 20), disulfide wit human-mouse monoclonal IDEC-C2B8 kapa-chain, dimer (WHO)

Foreign Names

  • Rituximabum (Latin)
  • Rituximab (German)
  • Rituximab (French)
  • Rituximab (Spanish)

Generic Names

Brand Names

  • Mab Thera
    Roche, Slovenia
  • MabThera
    Dr. F. Hoffmann-Lja - Roche, Russian Federation; euro rx Arzneimittel GmbH, Austria; F. Hoffmann-La Roche LTD, Serbia; Haemato Pharm, Austria; Hoffmann-La Roche, Bosnia & Herzegowina; Hoffmann-La Roche Ltd, Latvia; Inopha, Austria; Productos Roche, Chile; Roche, Armenia; Roche, Argentina; Roche, Australia; Roche, Bangladesh; Roche, Belgium; Roche, Brazil; Roche, China; Roche, Colombia; Roche, Czech Republic; Roche, Germany; Roche, Denmark; Roche, Ecuador; Roche, Egypt; Roche, Spain; Roche, Finland; Roche, France; Roche, Georgia; Roche, Greece; Roche, Hong Kong; Roche, Croatia (Hrvatska); Roche, Hungary; Roche, Indonesia; Roche, Ireland; Roche, Israel; Roche, Iceland; Roche, Italy; Roche, Lebanon; Roche, Lithuania; Roche, Moldova; Roche, Myanmar; Roche, Mexico; Roche, Netherlands; Roche, Norway; Roche, New Zealand; Roche, Oman; Roche, Philippines; Roche, Poland; Roche, Portugal; Roche, Romania; Roche, Serbia; Roche, Sweden; Roche, Thailand; Roche, Tunisia; Roche, Turkey; Roche, Taiwan; Roche, Uruguay; Roche, Vietnam; Roche, South Africa; Roche Products, United Kingdom; Roche Registration, Austria
  • Reditux
    Complex Therapeutics, Chile; Dr Reddy's, Vietnam; Dr Reddy's Lab, Myanmar
  • Rituxan
    Biogen Idec, United States; Genentech, United States; Roche, Canada; Zenyaku Kogyo, Japan


BANBritish Approved Name
DCFDénomination Commune Française
ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name
WHOWorld Health Organization

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.